Focus on ziprasidone: a review of its use in child and adolescent psychiatry.

OBJECTIVE: To review published literature regarding ziprasidone in child and adolescent psychiatry.
METHODS: A literature review was conducted using the medline search term: 'ziprasidone' with limits: Human trials, English language, All Child (Age 0-18). Additional articles were identified from reference information and poster presentation data.
RESULTS: Two randomized controlled trials and five prospective open-label studies have been conducted with ziprasidone. Additionally, several case reports and case series are reviewed. Ziprasidone has a greater propensity for QT(c) prolongation and risk for fatal arrhythmias compared to other atypical antipsychotics. Careful history taking regarding presence of congenital long QT syndrome is essential. Given limited clinical experience, electrocardiogram monitoring at baseline and following attainment of ziprasidone target dosage is warranted. No deaths from overdose have been reported in children and adolescents. Ziprasidone has a low potential for extrapyramidal side effects. Prolactin changes are small and transient. Lethargy, drowsiness, agitation and tachycardia were the most common adverse effects in randomized trials. Body weight changes with ziprasidone were comparable to placebo-treated subjects.
CONCLUSION: At present, ziprasidone should be considered a second or third-line option for a limited set of conditions. A role may exist for ziprasidone in patients who have experienced significant metabolic adverse effects with other atypical antipsychotics.